Lodosyn

Active Ingredient(s): Carbidopa
FDA Approved: * April 25, 1977
Pharm Company: * BRISTOL MYERS SQUIBB
Category: Parkinsons

Carbidopa (Lodosyn) is a drug given to people with Parkinson's disease in order to inhibit peripheral metabolism of levodopa. This property is significant in that it allows a greater proportion of peripheral levodopa to cross the blood–brain barrier for central nervous system effect. Contents 1 Pharmacology 2 pharmacology 2 3 Synthesis 4 References 5 External links Pharmacology Carbidopa inhibits aromatic-L-amino-acid decarboxylase (DOPA decarboxylase or DDC),[1] ... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Lodosyn LODOSYN;711
Lodosin 25 mg Oral Tablet
NDC: 25010-711
Labeler:
Aton Pharma, Inc
Lodosin 25 mg Oral Tablet
NDC: 0179-0125
Labeler:
Kaiser Foundation Hospitals
Lodosyn 25 mg Oral Tablet
NDC: 69189-0711
Labeler:
Avera Mckennan Hospital